Probiotics are usually defined as live microbial food ingredients beneficial to health which comprise of normal commensally bacteria as a part of the healthy human gut microflora. Different species of microorganisms such as lactic acid bacteria (Bifidobacteriumand Lactobacillusspp.) or yeasts have been proposed for human use.Nosocomial infections occur worldwide and affect both developed and poor countries.The most common organisms causing nosocomialinfection in neonates include Staphylococcus, Pseudomonas aeruginosa,Escherichiacoli,Klebsiella, and Candida.There is preliminary evidence that probiotic type microorganisms may control the growth of nosocomial pathogens.The aim of this review is to consider the current evidence on the effects of probiotics for control of nosocomial infections.
INTRODUCTION
Probiotics can be defined as nonpathogenic microorganisms that, when ingested, exert a positive influence on the health of the host. They consist of either yeast or bacteria, especially lactic acid bacteria. The most commonly used organisms in probiotic products belongs to Lactobacillus and Bifidobacterium spp., Other organisms have also been used including Bacillus spp., and yeast such as Saccharomyce boulardii (Darsanaki and Aliabadi, 2013) . In Table 1 are listed some of the known probiotics available (Mombelli and Gismondo, 2000) .
Probiotics can produce inhibitory compounds such as lactic acid, bacteriocin, hydrogen peroxide, acetaldehyde anddiacetyl. These compounds are able to inhibit the growth of pathogenic microorganisms (Zapata, 2013 (Table. 2) (Polin and Saiman, 2003).
There is preliminary evidence that probiotic type microorganisms may control the growth of nosocomial pathogens (Falagas and Makris, 2009 ).The aim of this review is to consider the current evidence on the effects of probiotics for control of nosocomial infections.
Control of Nosocomial Infections by Probiotics
Due to concerns regarding development of antibiotic resistance in hospitals, rising healthcare costs and lack of new antimicrobial classes being developed, probiotics have been considered a good prophylactic or therapeutic alternative in numerous conditions. Probiotics do not have the risk of antimicrobial resistance and offer practical benefits like low-cost preparation, long shelf life, and ease of administration (Oudhuis et al, 2011) .We identified 29studies involving in-vitro experiments on the potential role of probiotics in the inhibition of nosocomial pathogens (bacterial or fungal) ( Table  3) .
CONCLUSION
However, there are still many questions to be answered before probiotics can be used routinely as therapy. At presence, with increasing of the antibiotic resistance and side effects of chemical drugs, it seems, we need to use alternative remedies. Probiotics can have therapeutic application in future. 
